Knee osteoarthritis is one of the most common reasons people in their 40s, 50s, and 60s find themselves searching for options beyond what their orthopaedic surgeon has offered. Painkillers manage symptoms. Physiotherapy helps with function. Steroid injections provide temporary relief. And surgery — whether a partial or total knee replacement — is a significant undertaking that comes with recovery time, risks, and the reality that the joint it replaces is not the same as the one it removes.
For a growing number of patients, UC-MSC stem cell therapy has become a serious option to understand and evaluate. This guide explains what the science shows, who this treatment is appropriate for, what the process involves, and why the clinical environment matters as much as the cells themselves.
What Is Knee Osteoarthritis?
Knee osteoarthritis is a degenerative joint disease. Over time, the cartilage that lines and cushions the knee joint wears down. As it thins, bones begin to move closer together, friction increases, and the joint becomes inflamed. The result is pain, stiffness, reduced range of motion, and progressive loss of function.
It is primarily a disease of aging and mechanical wear, though it can be accelerated by previous injury, obesity, genetics, and repetitive joint loading. Osteoarthritis does not develop overnight — it progresses through stages, from early cartilage softening to advanced joint space narrowing visible on X-ray.
The reason it is so difficult to treat is not that the pain cannot be managed. It is that the underlying structural damage continues regardless of how well symptoms are controlled.
Why Cartilage Does Not Heal
Cartilage is one of the few tissues in the body with almost no natural regenerative capacity. It has no blood vessels running through it. The cells that maintain it — chondrocytes — are sparse and slow-dividing. When cartilage is damaged, the body has no reliable mechanism to replace what was lost with tissue of equivalent quality.
This is why osteoarthritis tends to be progressive rather than self-limiting. Inflammation in the joint creates a cycle: cartilage damage releases inflammatory signals, those signals attract immune cells, and the resulting inflammation damages cartilage further. Without intervention that breaks this cycle, the joint continues to deteriorate.
Standard treatments work around this reality. They reduce inflammation and pain, or they mechanically replace the joint. None of them address cartilage preservation at a biological level. This is where stem cell therapy enters the picture.
How UC-MSCs Work — Signalling, Not Replacement
The most important thing to understand about UC-MSC therapy for knee osteoarthritis is that it does not work by replacing lost cartilage. This is a common misconception. UC-MSCs do not become new cartilage cells and fill the gaps in a damaged joint.
They work through a different mechanism entirely — signalling. When introduced into the joint space, UC-MSCs release a range of growth factors and anti-inflammatory molecules that communicate with the surrounding tissue. They reduce the inflammatory environment that is driving cartilage breakdown. They stimulate the joint’s own cells to repair and maintain tissue more effectively. They help interrupt the damage cycle.
The effect is more like resetting the joint environment than rebuilding it. Patients experience reduction in pain and inflammation, improved joint function, and in some cases, stabilisation of cartilage loss — not because new cartilage has been deposited, but because the conditions destroying the existing cartilage have been modulated.
A 2024 dose-escalation clinical trial published in Stem Cells Translational Medicine assessed UC-MSC intra-articular injection in knee osteoarthritis patients. All doses used were safe. Significant reductions in pain and inflammation were observed across dose groups. The researchers confirmed that UC-MSCs demonstrated clinical benefit through their immunomodulatory and anti-inflammatory signalling activity.
A 2024 meta-analysis published in PMC, pooling data from randomised controlled trials on UC-MSC therapy for knee osteoarthritis, found that intra-articular injection improved both pain scores and joint function compared to control groups, with stable and consistent results across the included studies.
Who Is a Candidate?
The patients most likely to benefit from UC-MSC therapy for knee osteoarthritis fall into a clear profile. Ideal candidates are those with mild to moderate osteoarthritis — generally corresponding to grades 2 or 3 on the Kellgren-Lawrence scale — who have persistent pain and functional limitation despite conservative treatment.
In practical terms, this is the patient who has tried physiotherapy and found it insufficient, who relies on anti-inflammatories more than they would like, and who is not yet at the point of bone-on-bone damage requiring replacement. They are looking for something that might slow the progression of the disease and restore a meaningful level of function.
Other factors that influence candidacy include the patient’s overall health status, body weight, degree of joint deformity, and absence of contraindications such as active infection, inflammatory arthritis, or recent corticosteroid injection. Patients who are immunocompromised or on anticoagulant therapy require careful evaluation.
Every candidate should be assessed individually by a physician with access to imaging. A clinical decision made without current X-rays or MRI is not a clinical decision — it is a guess.
When Surgery Is More Appropriate
Stem cell therapy is not a substitute for surgery in all cases. Advanced osteoarthritis — grade 4 on the Kellgren-Lawrence scale, characterised by severe joint space narrowing, bone-on-bone contact, and significant structural deformity — is unlikely to respond meaningfully to any regenerative intervention. At that stage, the joint environment is too compromised for signalling-based therapy to produce significant benefit.
For these patients, total knee replacement remains the most evidence-based intervention for restoring function and eliminating pain. A responsible physician will say this directly. If a clinic suggests that stem cell therapy can replace the need for surgery in a patient with end-stage osteoarthritis, that claim should be treated with caution.
In some cases, UC-MSC therapy has a role alongside surgery — as a pre-surgical intervention to reduce inflammation, or in earlier-stage disease to delay the point at which surgery becomes necessary. These nuances require individual assessment.
How Many Cells Are Typically Used?
Dosing for intra-articular UC-MSC injection is not yet universally standardised, and this is an active area of research. Clinical studies have used a range of doses, typically between 20 million and 100 million cells per injection.
A 2025 meta-analysis published in PMC examined the dose-response relationship across randomised controlled trials on MSC injection for knee osteoarthritis. It found that lower doses — at or below 25 million cells — were associated with significant improvement in pain and function scores at 12 months. Higher doses did not consistently produce additional benefit. This is an important finding: more cells does not automatically mean better outcomes, and dose optimisation matters.
The appropriate dose for any individual patient depends on the severity of the condition, the patient’s body weight and immune status, and the clinical protocol being used. These decisions should be made by a physician, not a standard package.
What to Expect After Injection
The injection itself is typically performed intra-articularly — directly into the knee joint — and takes a short time. Most patients go home the same day.
In the days following treatment, some patients experience mild swelling or discomfort at the injection site. This is common and generally resolves within a few days. It reflects the joint responding to the introduction of biological material, not a sign of adverse reaction.
Meaningful clinical improvement — reduced pain, improved mobility — typically begins to emerge over four to eight weeks. The full effect of a single treatment course is generally assessed at three to six months. Some patients respond more quickly; others take longer. A single injection is the most common approach, though some protocols include repeated dosing depending on clinical response.
Patients are typically advised to avoid strenuous physical activity and anti-inflammatory medications in the days immediately following injection, as these can interfere with the local cellular environment. Your physician will provide specific instructions based on your case.
Safety and Monitoring
UC-MSC intra-articular injection for knee osteoarthritis has a well-documented safety profile across multiple clinical trials. No serious adverse events attributable to the treatment have been reported in published studies. Minor reactions — mild swelling, temporary discomfort — occur in some patients and resolve without intervention.
As with any invasive procedure, the risks associated with the injection technique itself — such as infection — are present, though rare when performed under proper sterile conditions. This is another reason that the clinical environment and physician experience matter.
Post-treatment monitoring should include follow-up consultations, functional assessment, and imaging review at defined intervals. Clinics that treat and discharge without structured follow-up are not providing a complete service.
Why Choose a Surgeon-Led Program
Knee osteoarthritis is a structural, biomechanical condition. Understanding whether a patient is a suitable candidate for stem cell therapy — and what the realistic outcome is likely to be — requires clinical expertise in orthopaedic medicine, not just familiarity with regenerative therapies.
A surgeon-led program brings several things that cannot be replicated by a non-surgical clinic. First, accurate staging of the disease using imaging reviewed by a physician trained in joint pathology. Second, an honest assessment of whether stem cell therapy, surgery, or a combination approach is most appropriate for this patient at this time. Third, delivery of treatment with the anatomical precision that intra-articular injection requires.
At EDNA Wellness, all cases involving knee osteoarthritis are reviewed by orthopaedic surgeons and neurosurgeons before treatment is recommended. Stem cell therapy is offered only where clinical indication supports it. Patients for whom surgery is the more appropriate option are told this clearly.
About EDNA Wellness
EDNA Wellness is a surgeon-led regenerative medicine center in Bangkok, specializing in orthopedic and neurological conditions using Umbilical Cord–Derived Mesenchymal Stem Cells (UC-MSCs).
All cases are reviewed by orthopedic surgeons and neurosurgeons, with a focus on clinical indication, patient safety, and realistic treatment expectations. Stem cell therapy is recommended selectively, and alternative treatments are considered when more appropriate.
For more information or to book a consultation:
LINE: @ednawellness
WhatsApp: +66 (0) 64 505 5599
References
- Matas, J. et al. (2024). A phase I dose-escalation clinical trial to assess the safety and efficacy of umbilical cord-derived mesenchymal stromal cells in knee osteoarthritis. Stem Cells Translational Medicine, 13(3), 193–203. https://pmc.ncbi.nlm.nih.gov/articles/PMC10940813/
- Xu, T. et al. (2024). Effects of umbilical cord mesenchymal stem cells in the treatment of knee osteoarthritis: a systematic review and meta-analysis. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC11575993/
- Ozdemir, R.K. et al. (2025). Regenerative therapy in osteoarthritis using umbilical cord-origin mesenchymal stem cells: a critical appraisal of clinical safety and efficacy through systematic review and meta-analysis. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12688636/
- Almutairi, K. et al. (2025). Efficacy of a single intra-articular injection of mesenchymal stem cells for knee osteoarthritis: a dose-focused meta-analysis of randomized controlled trials. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12398016/